Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: April Update

Performance overview
Value at beginning of month: $97,541.67
Value at end of month: $96,196.79
Month over month change: -1.38%
Total CAGR: -11.18%

Related indices, monthly change
NASDAQ: +2.29%
IVV (iShares Core S&P 500): +1.38%
IBB (iShares NASDAQ Biotechnology Index): +1.49%
MXI (iShares Global Materials): +0.42%
VEGI (iShares MSCI Global Agriculture Producers): +1.49%

Individual performances

Mixed performances in the index during April, but Genscript coming back to Earth dragged the index to losses. Novozymes continued to climb, and it is up over 25% on the year.

Changes made to index


Allocation as of April 29, 2017

Calvin Schmidt Synthetic Biology Index: May Update

Calvin Schmidt Synthetic Biology Index: March Update